

SPARC/Sec/SE/2025-26/61

February 03, 2026

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Scrip Symbol: SPARC

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 532872

Dear Sir/Madam,

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release about “Receipt of Priority Review Voucher associated with Sezaby® Approval”, which we shall be released after this intimation.

This is for your information and dissemination.

For Sun Pharma Advanced Research Company Ltd.

Kajal Damania
Company Secretary and Compliance Officer

Encl: As above



FOR IMMEDIATE RELEASE

SPARC Announces Receipt of Priority Review Voucher associated with Sezaby® Approval

Grant of Priority Review Voucher underscores SPARC's commitment to addressing high unmet medical needs

SPARC intends to utilize the voucher to further accelerate its pipeline

MUMBAI, February 3, 2026, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that the United States Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby®.

A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases, that can be redeemed to receive a priority review for a subsequent, separate drug application.

"Receiving this Priority Review Voucher is a significant milestone for SPARC and a testament to our commitment to addressing the urgent, unmet needs of patients," said Anil Raghavan, CEO of SPARC. "This award not only recognizes the therapeutic value of Sezaby® but also provides SPARC with additional strategic flexibility to accelerate our pipeline development to bring more therapies to patients faster."

About Sezaby®:

SEZABY® is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection. It was approved by FDA for the treatment of neonatal seizures.

About SPARC (CIN: L73100GJ2006PLC047837):

Sun Pharma Advanced Research Company Ltd. ('SPARC') is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life.



Media Contacts:

Jaydeep Issrani
Tel +91 22 66455645, Extn: 5787
Tel Direct +91 22 6645 5787
Mobile +91-9820216916
E mail jaydeep.issrani@sparcmail.com

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life

Registered office : Plot no. 5&6/1, Savli GIDC Estate, Manjusar 391775, District: Vadodara, Gujarat, India.